ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2025
CVR: 32323596
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.
- Gross Profit
- EUR 229,581,000
- Profit/Loss
- EUR 134,982,000
- Equity
- EUR -372,183,000
- Total Assets
- EUR 58,737,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 229.6M EUR | 135M EUR | -372.2M EUR | 0 |
| 2024 | - | -34K EUR | -139K EUR | -507K EUR | 0 |
| 2023 | - | -112.3M EUR | -119M EUR | -368.1M EUR | 0 |
| 2022 | - | -66.6M EUR | -72.2M EUR | -249.2M EUR | 0 |
| 2021 | - | -58M EUR | -61.8M EUR | -177M EUR | 0 |
Official annual report
How creditworthy is ASCENDIS PHARMA BONE DISEASES A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2024. Gross profit came to DKK -34,018, and the net result was DKK -139,088.
About ASCENDIS PHARMA BONE DISEASES A/S
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.